A Phase 3 interventional study of Ambroxol Hydrochloride (420mg) and Placebo in Parkinson Disease, sponsored by University College, London. Recruiting at 15 sites in United Kingdom. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by University College, London · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Parkinson Disease by University College, London — 4 open to participants now, 4 under way, 2 of them phase 3. Parkinson Disease · University College, London.
Among the 16 studies in Parkinson Disease by University College, London, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 3, and was the 14th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →4 of the 16 studies in Parkinson Disease by University College, London are open now, in 1 country. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 30+
University College, London · Sites in United Kingdom
Ages 18–90
University College, London · Sites in United Kingdom
Ages 16+ · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 4
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 56 across the 12 interventional studies, 1,080 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University College, London is the lead sponsor of 652 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
1 of the studies in Parkinson Disease by University College, London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02760108University College, LondonParkinson's Families Project | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Parkinson Disease by University College, London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.
This is a 104-week, randomized, double-blind, multi-centre, parallel group, placebo-controlled clinical trial of ambroxol hydrochloride in patients with PD, with a 26-week open-label extension phase. Participants will undergo screening to evaluate their eligibility to participate in the trial. All eligible participants will be randomised to receive either ambroxol hydrochloride (420mg) or it's matching placebo in a 1:1 ratio three times a day for 104 weeks, including a 2-week dose escalation period. Once the end of the blinded treatment has been reached, all participants will enter the open-label extension phase and will receive ambroxol hydrochloride (420mg) three times a day for 26 weeks, including a 2-week dose escalation period. All clinical staff, study investigators, and participants will be blinded to study assignments throughout the entirety of the trial.
There will be an optional sub-study including 106 participants in which a cerebrospinal fluid (CSF) sample will be taken on two occasions via a Lumbar Puncture procedure to measure ambroxol drug levels, assess whether the glucocerebrosidase enzyme has been stimulated and the levels of other substances thought to be associated with the development of PD and confirm whether the study drug has penetrated the cerebrospinal fluid and Central Nervous System.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any or unstable medical or surgical condition that in the opinion of the Investigator may; put the participant at risk when participating in the study, influence the results of the study or affect the participants ability to take part in the study, as determined by medical history, physical examinations, (ECG) or laboratory tests. Such conditions may include:
A. Impaired renal function with \<50ml/min at screening visit.
B. Moderate/Severe hepatic impairment.
C. A major cardiovascular event (e.g., myocardial infarction, acute coronary syndrome, compensated congestive heart failure, pulmonary embolism, coronary revascularisation) that occurred within 6 months prior to the screening visit.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ambroxol hydrochloride (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase. n=165
Drug: Ambroxol Hydrochloride (420mg)
Participants will receive ambroxol hydrochloride matching placebo (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride matching placebo 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase. n=165
Drug: Placebo
Oral tablet
Also known as: Ambroxol
Oral tablet
Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- III score from baseline to Week 104.
The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Comparison of MDS-UPDRS Parts I-III total score at 104 weeks between participants according to treatment allocation will be made. Parts I and II are measured in the practically defined ON medication state and Part III is measured in the practically defined OFF medication state. Parts I and II are historical data assessed by an examiner and are designed to rate mentation, behaviour and mood; Part III is done as a motor examination at the time of a visit. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II and III (Range: 0 to 236). Higher score indicative of worse outcome.
Time frame: Baseline; Week 104
Motor signs of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score in the OFF medication state from baseline to Week 104.
This component of the MDS-UPDRS scale (Section III) assesses the motor signs of PD and will involve a motor examination at the time of a visit. The score ranges from 0 to 132. Higher score is indicative of worse outcome.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Motor complications of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV score in the ON medication state from baseline to Week 104.
This component of the MDS-UPDRS scale (Section IV) assesses two motor complications, dyskinesias and motor fluctuations using historical and objective information. The score ranges from 0 to 24. Higher score indicative of worse outcome.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The non-motor impact of PD on patients using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I score in the ON medication state baseline to Week 104.
This component of the MDS-UPDRS scale (Section I) assesses the non-motor impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 24. Higher score indicative of worse outcome.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The motor aspect impact of PD of patients experiences on daily living using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II score in the ON medication state from baseline to Week 104.
This component of the MDS-UPDRS scale (Section II) assesses the motor aspect impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 52. Higher score indicative of worse outcome.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) tremor score from baseline to Week 104.
The tremor components of the MDS-UPDRS scale
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) non-tremor score from baseline to Week 104.
The non-tremor components of the MDS-UPDRS scale
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Cognitive impairment using the Montreal Cognitive Assessment from baseline to Week 104.
A 30 question test which assesses mild cognitive impairment by checking participant orientation, short-term memory, executive function, language, abstraction, naming of animals, attention and a clock drawing test. Maximum score= 30. Lower scores indicative of worse outcome.
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Patient reported measure of health status and quality of life using the Parkinson's disease 39 item Quality of Life questionnaire from baseline to Week 104.
A questionnaire which assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living. The 39 item questionnaire offers a patient reported measure of health status and quality of life and is the most frequently used disease-specific health status measure. Maximum score = 156. Higher score= worse outcome.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Symptom improvement from baseline to Week 104 using the Patient Global Impression of Change from baseline to Week 104.
A 1 item questionnaire which asks a participant to report their own impression of change in their clinical status. Maximum score = 7. Higher score= worse outcome.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Quality-of-Life outcome differences between the two treatment groups from baseline to Week 104, as measured by the descriptive system for health-related quality of life, EQ-5D-5L.
The EQ-5D-5L is a participant self-reported questionnaire which evaluates the generic quality of life at the time of completion. It comprises of one question for each of the five dimensions ;no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. An Visual Analogue Scale is also used and is a scale measured from 0 -100 scale where patients are asked to indicate their overall health on the day of questionnaire completion. Maximum score = 100. Lower score = worse outcome.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Non-motor symptoms of PD from baseline to Week 104 , as measured by the Non-Motor Symptoms Scale.
The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. Maximum score = 360. Higher score = worse outcome.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
PD progression measured using Parkinson's Disease Comprehensive Response from baseline to Week 104
A composite approach integrating three standard outcome measures PDCORE = (1 × change in OFF state motor score) + (2 × change in OFF state ADL score) - (10 × change in total good-quality ON time per day). Higher score = worse outcome.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Assessment of postural instability and falls from baseline to Week 104 using the Dresden Falls Questionnaire.
A self-reported assessment of falls, near falls, fear of falling, fall-related injuries, and causes of falls for patients with Parkinson's disease. Maximum score = 12. Higher score = worse outcome.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Symptom severity, treatment response and the efficacy of treatment from baseline to Week 104 using the Clinical Global Impression of symptom severity and improvement scales.
Research team assessment. The CGI has two components-the CGI-Severity, which rates illness severity, and the CGI-Improvement, which rates change from the initiation (baseline) of treatment. Maximum score = 14. Higher score = worse outcome.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in pulse (bpm) from baseline to Week 104
Vital signs
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in blood pressure (mmHg) from baseline to Week 104
Vital signs
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in temperature (°) from baseline to Week 104
Vital signs
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in respiratory rate (breaths per minute)from baseline to Week 104
Vital signs
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Body Mass Index (weight and height will be combined to report BMI in kg/m^2) from baseline to Week 104
Vital signs
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Red Blood Cell Count (10^12/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haemoglobin (g/dL) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haematocrit (%) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Platelets (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in White Blood Cell Count (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Neutrophils (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Eosinophils (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Basophils (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Lymphocytes (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Monocytes (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Urea (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Sodium (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Potassium (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Creatinine (µmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Total Bilirubin (µmol/L)from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alkaline phosphatase (IU/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alanine transaminase (IU/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Aspartate Aminotransferase (IU/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Uric Acid (mg/dL) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Bicarbonate (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Chloride (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by the occurrence / severity of treatment related Adverse Events assessed by CTCAE v5.0 from baseline to Week 104
Number of participants with treatment related adverse events assessed by CTCAE v5.0 from baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Time to initiation of rescue medication
Length of time until initiation of rescue medication from baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Change in levodopa equivalent dose at 104 weeks
Calculated levodopa equivalent dose from baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
The association between ambroxol, the glucocerebrosidase enzyme and other proteins associated with the development of PD measured by glucocerebrosidase enzyme activity and other protein markers in blood and cerebrospinal fluid (CSF) samples.
There is evidence of a reciprocal relationship between PD development and glucocerebrosidase enzyme activity. Testing levels of glucocerebrosidase enzyme activity in blood and CSF samples is used to assess the ability of ambroxol to modulate glucocerebrosidase enzyme activity.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
The association between ambroxol and alpha-synuclein levels in blood and cerebrospinal fluid (CSF) samples from baseline to Week 104.
Alpha-synuclein is a key protein involved in Parkinson's disease (PD) pathology. Testing levels of Alpha-synuclein in blood and CSF samples is used to access the ability of ambroxol to modulate Alpha-synuclein activity.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
The association between ambroxol and glycerylceramide, neurofilament light chain and lipid levels in cerebrospinal fluid (CSF) samples from baseline to Week 104.
Testing levels of glycerylceramide, neurofilament light chain and lipid levels in CSF samples is used to access the ability of ambroxol to modulate their activity.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Affect of GBA status on all measurement outcomes for both treatment arms from baseline to Week 104.
Analysis of all outcome data from both treatment arms in comparison to GBA status at screening.
Time frame: Baseline and Week 104
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- IV score from baseline to Week 130.
The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104 and week 130. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II, III and IV. Higher score indicative of worse outcome.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104; Week 130
Comparison of change in the gut microbiome composition from baseline to Week 104.
Faecal samples will be collected to analyse the gut microbiome.
Time frame: Baseline and Week 104.
Comparison of The Smell Identification Test [UPSIT] score change from baseline to week 104.
Smell identification to test the function of an individual's olfactory system.
Time frame: Baseline and Week 104.
Plan to share: Undecided
Started Feb 2025 (actual). Primary completion is estimated for Feb 2029, 48 months after the start.
Of 68 phase 3 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 48 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ambroxol